• Pancreatic cancer patients

• Ampullary cancer patients

• Locally advanced pancreatic cancer patients

• Patients requiring pancreatoduodenectomy

Taipei Veterans General Hospital Pancreatic Cancer Treatment and Research Center specializes in treating pancreatic and ampullary cancer using robotic-assisted minimally invasive surgery combined with chemotherapy and carbon-ion radiotherapy, performing complex pancreatoduodenectomy and achieving breakthroughs in pancreatic cancer treatment.

• Robotic-assisted minimally invasive pancreatoduodenectomy

• Significantly reduced blood loss: median 200mL vs conventional 500mL

• Substantially reduced delayed gastric emptying

• Lower complication rates

• Superior lymph node harvesting

• Rapid recovery: patients mobilize 1-6 days post-operatively

• Conversion surgery for initially unresectable tumors using chemotherapy combined with carbon-ion radiotherapy

• Patient satisfaction rate exceeding 99%

• Over 686 robotic-assisted minimally invasive pancreatoduodenectomy surgeries completed

• Surgical success rate of 98.7%

• Over 80 pancreatic cancer carbon-ion radiotherapy cases

• 3 conversion surgery cases for initially unresectable locally advanced patients

• 5-year survival rate increased to 36.9% (pancreatic head cancer), leading globally

• Pancreatic head cancer 5-year survival rate 36.9%

• Ampullary cancer 5-year survival rate 63.9%

• Distal CBD cancer 5-year survival rate 58.1%

• Duodenal cancer 5-year survival rate 62.0%

• Mortality rate reduced from 5% to 1.3%

• No significant difference in lymph node harvesting between conventional and robotic surgery (median 18 vs 16, p=0.038)

• Blood loss median 200mL in minimally invasive surgery, significantly lower than conventional 500mL (p<0.001)

• Delayed gastric emptying rate significantly reduced (p=0.004)

• Lower complication rates (p=0.035)

• Patients can mobilize 1-6 days post-operatively

• Patients can travel long distance by plane 1.5 months post-operatively

• Overall patient surgery satisfaction rate 99% (104/105 patients willing to recommend)

• Post-operative period <12 months recommendation rate 98.4% (63/64 patients)

• Post-operative period >12 months recommendation rate 100% (41/41 patients)

• Conversion surgery patients overall treatment satisfaction 100%

• International patients witnessed treatment outcomes and miracles

• 138 academic papers on pancreatic and pancreatoduodenectomy surgery

• 30 academic papers on robotic-assisted pancreatic minimally invasive surgery

• Over 132 international and domestic lectures and research presentations

• 2018 Swiss International Hepatobiliary Pancreatic Surgery Society lecture

• 2019 Seoul Asia-Pacific Hepatobiliary Pancreatic Surgery Society lecture

• Authored chapter on pancreatoduodenectomy techniques in international textbook "Pancreas Cancer"

• Invited to International Guidelines Meeting in MIS Pancreas Resection

• Invited to provide technical demonstrations at prestigious Asian hospitals including Seoul University Hospital and Kyoto University Hospital

• Trained 37 domestic talents distributed across major hospitals nationwide

• Trained 39 Asian talents (19 from Japan, 10 from Korea, 2 from Indonesia, 2 from Singapore, 1 from Malaysia, 1 from India, 3 from Thailand)

• Trained 6 international talents (1 from Turkey, 1 from Israel, 3 from Ethiopia, 1 from Slovakia)

• Established "Robotic-Assisted Pancreatic Surgery Physician Certification" system

• Established international guidelines for pancreatic minimally invasive surgery

• Combined with carbon-ion radiotherapy to become a world-class pancreatic cancer treatment center

• Achieved "impossible mission" bringing hope to pancreatic cancer patients globally